Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 16/20 | 0.48 |
| ▸ | CCL5 | P13501 | 9/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290781 | 0.90 | CCR5 (0.47) | CCR5CCL5 | |
| SCHEMBL4691489 | 0.87 | CCR5 (0.43) | CCR5CCL5KCNH2HCRTR1HCRTR2 | |
| SCHEMBL4693570 | 0.86 | CCR5 (0.52) | CCR5CCL5KCNH2 | |
| SCHEMBL3286468 | 0.86 | CCR5 (0.52) | CCR5CCL5KCNH2 | |
| SCHEMBL4697962 | 0.84 | CCR5 (0.43) | CCR5CCL5KCNH2HCRTR1HCRTR2 | |
| SCHEMBL5525314 | 0.82 | CCR5 (0.39) | CCR5CCL5KCNH2HCRTR1HCRTR2 | |
| SCHEMBL4696229 | 0.82 | CCR5 (0.42) | CCR5CCL5KCNH2HCRTR1HCRTR2 | |
| SCHEMBL4698164 | 0.80 | CCR5 (0.42) | CCR5CCL5KCNH2HCRTR1HCRTR2 | |
| SCHEMBL4752682 | 0.79 | CCR5 (0.40) | CCR5CCL5KCNH2HCRTR1HCRTR2 | |
| SCHEMBL4757058 | 0.79 | CCL5 (0.43) | CCR5CCL5KCNH2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987035-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093515-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN LA-ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20080299132-A1 | Synergistic compositions for treating HIV-1 | ROCHE PALO ALTO LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | CCR5 1/4885CCL5 14/4885KCNH2 1746/4885 |
| US-20080299132-A1 | Synergistic compositions for treating HIV-1 | CCR5, CD4, HAVCR2 | CCR5 1/4885CCL5 5/4885KCNH2 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.